<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6458">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03022851</url>
  </required_header>
  <id_info>
    <org_study_id>Occ2016_04</org_study_id>
    <secondary_id>CIV-16-07-016324</secondary_id>
    <nct_id>NCT03022851</nct_id>
  </id_info>
  <brief_title>The Prophet Trial - Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Patients With Pulmonary Hypertension</brief_title>
  <official_title>Prospective, Non-randomized, Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Patients With Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Occlutech International AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Occlutech International AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate safety and efficacy of Occlutech® AFR device in patients with
      severe pulmonary hypertension (PH).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of Serious adverse device effects (SADES) within 3 month after implantation, including deaths, systemic embolism or device embolizations.</measure>
    <time_frame>0-3 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of all Serious Adverse Events (SAE) and (Serious) Adverse Device Efffects (S)ADEs between 3-6 month post implantation</measure>
    <time_frame>3-6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of a secure placement of the device and of right-to-left shunt through the AFR device immediately after implantation and 3 month and 6 month after procedure.</measure>
    <time_frame>0-6 month</time_frame>
    <description>The secondary efficacy endpoint will be determined via assessment by color-doppler echocardiography and angiography/fluoroscopy and requires both of:
Device placed in situ [as assessed by the investigator] Evidence of RIGHT TO LEFT shunt through the AFR device [as assessed by the investigator]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in number of syncopal events due to pulmonary hypertension in the 3 and 6 months after implantation</measure>
    <time_frame>0-6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Occlutech AFR Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who will get the AFR Device implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Occlutech AFR Device</intervention_name>
    <description>Catheter-guided transeptal placement of an AFR device following balloon atrial septostomy (BAS) -procedure.</description>
    <arm_group_label>Occlutech AFR Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age is ≥ 6 years.

          -  Patient consents to participation

          -  Patient agrees to comply with the follow-up schedule

          -  Right heart failure, chronic and clinically severe

          -  Syncope due to acute Pulmonary Hypertension episodes

          -  Severe pulmonary hypertension as evident by echocardiography or catheterisation

          -  Patient has had a successful ballon atrial septostomy (BAS)- procedure and is in a
             stable hemodynamic state, as assessed by the investigator

        Exclusion Criteria:

          -  Local or generalized sepsis or other acute infection(s)

          -  Thrombophilic coagulation disorder

          -  Allergy to nickel and/or titanium and/or nickel/titanium-based materials

          -  Allergy to anti-platelet, -coagulant, or -thrombotic therapy

          -  Intolerance to contrast agents

          -  Participation in other medical trials shorter than 30 days before the intended AFR
             implantation procedure

          -  Pregnancy - (assessed in patients with child bearing potential by urine dip stick)

          -  Occluded inferior vena cava access

          -  Previous Atrial septum defect (ASD)/ Patent Foramen Ovale (PFO) closure device in
             place

          -  Intracardiac thrombus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 12, 2017</lastchanged_date>
  <firstreceived_date>January 10, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
